Evidence map›Paper›PMID 33115952›Full record

ArticleScience translational medicine2020

A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease.

Juan M Bustamante, Fernando Sanchez-Valdez, Angel M Padilla, Brooke White, Wei Wang, Rick L Tarleton

Open access · greenAbstract read
In one paragraph

Article in Science translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 62 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Glycosomal Phosphoenolpyruvate Carboxykinase CRISPR/Cas9-Deletion and Its Role in Trypanosoma cruzi Metacyclogenesis and Infectivity in Mammalian Host.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. The epidemiology of Chagas disease in the Americas.Lancet regional health. Americas · 2024
    Review
  13. Review
  14. New insights intoFrontiers in immunology · 2024
    Review
  15. Article
  16. Article
  17. DIAGNOSIS AND TREATMENT OF A NATURAL INFECTION WITHJournal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Juan M BustamanteCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia, USA.ORCID 0000-0003-2902-7111
Fernando Sanchez-ValdezCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia, USA.ORCID 0000-0002-0045-0453
Angel M PadillaCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia, USA.ORCID 0000-0002-7907-5667
Brooke WhiteCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia, USA.ORCID 0000-0002-0441-1355
Wei WangCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia, USA.ORCID 0000-0001-7111-4687
Rick L TarletonCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia, USA. tarleton@uga.edu.ORCID 0000-0002-9589-5243
University of Georgia · USNational University of Salta · AR

Funding

Trypanosoma cruzi dormancy and its implications for therapeutic treatmentR01AI151148 · NIAID · UNIVERSITY OF GEORGIA · PI TARLETON, RICK L · 2020 to 2024
$2.4M
Mechanisms of persistence in Trypanosoma cruzi infectionR01AI124692 · NIAID · UNIVERSITY OF GEORGIA · PI TARLETON, RICK L · 2016 to 2020
$1.9M
A more effective drug treatment regimen for Trypanosoma cruzi infectionR21AI142469 · NIAID · UNIVERSITY OF GEORGIA · PI BUSTAMANTE, JUAN, TARLETON, RICK L · 2019 to 2020
$414k
Making benznidazole a better drug for Chagas diseaseR21AI108265 · NIAID · UNIVERSITY OF GEORGIA · PI TARLETON, RICK L · 2014 to 2015
$411k
NIAID NIH HHS R01 AI124692NIAID NIH HHS R01 AI151148NIAID NIH HHS R21 AI108265NIAID NIH HHS R21 AI142469
6 · The paper itself

Abstract

A major contributor to treatment failure in Chagas disease, caused by infection with the protozoan parasite

Indexed as

Chagas DiseasePharmaceutical PreparationsTrypanocidal AgentsTrypanosoma cruziAnimalsDisease Models, AnimalMicePharmaceutical PreparationsTrypanocidal Agents

Identifiers

PMID33115952
PMCPMC7926267
OpenAlexW3097226423

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.